Crispr Therapeutics AG vs Paycom Software Inc — how do they compare? Crispr Therapeutics AG trades at $53.97 (market cap $5.23B), while Paycom Software Inc trades at $211 (market cap $9.57B). The key difference: Paycom Software Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.71% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PAYC | |
|---|---|---|
Market Cap | $5.23B | $9.57B |
Sector | Health | Technology |
52-Week High | $76.78 | $233.89 |
52-Week Low | $44.34 | $113.59 |
Enterprise Value | $3.65B | $10.35B |
Dividend Yield | — | 0.71% |
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →